EN DE
STOCK COMPARISON

Mediobanca Banca di Credito Finanziario S.p.A vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Mediobanca Banca di Credito Finanziario S.p.A (MB) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 18, 2026.

As of Sep 18, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Mediobanca Banca di Credito Finanziario S.p.A trades at €28.89 versus a fair value of €19.64 (-32%), while Vertex Pharmaceuticals trades at $516 versus $566 (+10%).
Mediobanca Banca di Credito Finanziario S.p.A
MB.MI · EUR · Financials
-32%
upside to fair value
overvalued
Price€28.89
Fair Value€19.64
Quality58/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
+10%
upside to fair value
fairly valued
Price$516
Fair Value$566
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Mediobanca Banca di Credito Finanziario S.p.AVertex Pharmaceuticals
Valuation
19.5×P/E (TTM)28.8×
10.20×P/S (TTM)10.06×
2.37×P/B6.59×
38.2×EV/EBITDA23.8×
1.02×PEG1.72×
−32.0%Fair value upside+9.6%
4.3%Dividend yield0.1%
Profitability
56%Operating margin38%
0.63×EBIT margin trend (5Y)0.86×
12%Return on equity24%
1%Return on assets12%
Growth
6%Revenue growth (YoY)8%
7.9%Avg. growth/yr (3Y)10.6%
7.4%Avg. growth/yr (5Y)14.2%
+14.7%Value creation/yr+13.6%
Balance & size
0.7×Interest coverage (EBIT/interest)357.9×
2.56×Debt / equity0.03×
$27BMarket cap$123B
mixedGrowth qualityhealthy
Valuation multiples (P/E, P/S, P/B, EV/EBITDA) are shown but not scored here: the two companies sit in different sectors, and multiples only compare fairly between similar business models. PEG stays scored, as it relates the P/E to growth.

Vertex Pharmaceuticals leads: 4 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Mediobanca Banca di Credito Finanziario S.p.Aof which business quality 50 · market factors 81 Vertex Pharmaceuticalsof which business quality 77 · market factors 74
ProfitabilityMargins and returns on capital today
36
72
Quality GrowthAre margins and returns improving?
58
65
CashflowEarnings quality: real cash, not paper profit
51
79
Fin. StrengthBalance sheet, leverage, solvency risk
5
92
InvestmentDisciplined investing over empire-building
88
58
Low VolatilityCalm price path (market factor)
71
85
MomentumPrice trend over the last 3–12 months (market factor)
81
64
52W MomentumDistance to the 52-week high (market factor)
91
79
Net IssuanceShare count: buybacks or dilution?
100
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyMediobanca Banca di Credito Finanziario S.p.APrice €28.89Vertex PharmaceuticalsPrice $516
DCF Modelsn/a-12%close to the price$453
Earnings-Basedn/a0%close to the price$516
Dividend Discount-17%below the price€24.06-99%below the price$7.07
Multiples-29%below the price€20.59-46%below the price$278
Asset-Based-67%below the price€9.44-90%below the price$49.27
Growth DCFn/a-33%below the price$348
Economic Profit-48%below the price€14.94-51%below the price$254
Growth Earningsn/a+34%above the price$692
Minimum-67%below the price€9.44-99%below the price$7.07
Maximum-17%below the price€24.06+34%above the price$692
Median-39%below the price€17.77-39%below the price$313
Geometric mean-44%below the price€16.26-64%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Mediobanca Banca di Credito Finanziario S.p.A: 6 of 6 models see the stock below the current price.

Vertex Pharmaceuticals: 21 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Mediobanca Banca di Credito Finanziario S.p.A
Price €28.89
Fair Value €19.64
Bear €12.42Bull €24.55
Vertex Pharmaceuticals
Price $516
Fair Value $566
Bear $329Bull $1,262

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Mediobanca Banca di Credito Finanziario S.p.A · Financials

Quality score58 · above median
Fair value upside-32% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside+10% · above median

Bottom line

As of Sep 18, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Mediobanca Banca di Credito Finanziario S.p.A trades at €28.89 versus a fair value of €19.64 (-32%), while Vertex Pharmaceuticals trades at $516 versus $566 (+10%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Mediobanca Banca di Credito Finanziario S.p.A · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Mediobanca Banca di Credito Finanziario S.p.A

Microsoft vs NvidiaApple vs MicrosoftMicrosoft vs Taiwan Semiconductor ManufacturingCisco Systems vs Nvidia

Related to Vertex Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupApple vs Cisco SystemsBroadcom vs MicrosoftMicrosoft vs Micron Technology
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.